Clearmind Medicine Inc. (CMND) Income Statement
CMND FY2025 at a glance
Fiscal year ended October 31, 2025 · U.S. dollarsCMND revenue and net income
CMND growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CMND quarterly EPS vs estimates
CMND income statement
| FY2025 | FY2017 | |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of revenue | $49,364 | — |
| Gross profit | −$49,364 | — |
| Research & development | $2.0M | — |
| Sales, general & admin | $3.6M | — |
| Total operating expenses | $5.6M | $6,529 |
| Operating income | −$5.7M | −$6,529 |
| Interest income | $132,908 | — |
| Interest expense | $19,535 | — |
| Income before taxes | −$3.8M | −$6,529 |
| Income taxes | $70,438 | — |
| Net income | −$3.9M | −$6,529 |
| EBITDA | −$3.7M | −$6,529 |
| EPS (diluted) | −$15.27 | — |
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $14,218 | $13,901 | $13,318 | $12,836 | $12,522 | $11,978 | $12,031 |
| Gross profit | −$14,218 | −$13,901 | −$13,318 | −$12,836 | −$12,522 | −$11,978 | −$12,031 |
| Research & development | $586,197 | $644,036 | $637,344 | $417,382 | $720,288 | $449,521 | $458,428 |
| Sales, general & admin | $1.6M | $924,502 | $3.0M | $997,661 | $948,742 | $855,124 | $1.0M |
| Total operating expenses | $2.2M | $1.6M | $3.6M | $1.4M | $1.4M | $1.3M | $1.5M |
| Operating income | −$2.2M | −$1.6M | −$3.7M | −$1.5M | −$1.4M | −$1.3M | −$1.5M |
| Interest income | $106,961 | $42,025 | $64,649 | $24,659 | $32,593 | $41,648 | $34,008 |
| Interest expense | $5,306 | $4,233 | $4,103 | $6,238 | $9,192 | $7,873 | $8,710 |
| Income before taxes | −$904,061 | −$2.0M | −$3.8M | −$685,584 | −$1.3M | −$763,840 | −$1.0M |
| Income taxes | $3,230 | $3,311 | $3,957 | $2,194 | $8,257 | $20,673 | $39,313 |
| Net income | −$907,291 | −$2.0M | −$3.9M | −$687,777 | −$1.3M | −$784,513 | −$1.1M |
| EBITDA | −$2.2M | −$1.6M | −$3.8M | −$672,748 | −$1.3M | −$743,992 | −$1.0M |
| EPS (diluted) | −$0.57 | −$6.78 | −$33.17 | −$5.03 | −$9.84 | −$0.16 | −$0.24 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CMND's financial statements (latest annual report filed January 20, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CMND financial results
Clearmind Medicine reported no revenue in fiscal year 2025 (ended October 31, 2025). It had a net loss of $3.9 million. Diluted earnings per share came to −$15.27.
See the CMND stock overview for the latest quote and news, or the CMND chart for price history and technical indicators.
CMND income statement FAQ
Does Clearmind Medicine have revenue?
Clearmind Medicine reported no revenue for fiscal year 2025, which ended on October 31, 2025.
Is Clearmind Medicine profitable?
No. Clearmind Medicine reported a net loss of $3.9 million in fiscal 2025.
How much does Clearmind Medicine spend on research and development?
Clearmind Medicine spent $2.0 million on research and development in fiscal 2025.
What are Clearmind Medicine's earnings per share?
Clearmind Medicine earned $-15.27 per diluted share in fiscal 2025.
When does Clearmind Medicine's fiscal year end?
Clearmind Medicine's fiscal year ends in October. The latest annual report covers the year ended October 31, 2025 and was filed on January 20, 2026.